Healthcare [ 7/13 ] | Biotechnology [ 82/163 ]
NASDAQ | Common Stock
Anixa Biosciences, Inc., a clinical-stage biotechnology company, focuses on the treatment and prevention of cancer.
Its therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR- T, known as chimeric endocrine receptor T-cell (CER-T) technology.
The company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer " primarily triple negative breast cancer (TNBC), the lethal form of the disease, as well as a vaccine to prevent ovarian cancer.
Its vaccine technologies focus on immunizing against retired proteins that found to be expressed in certain forms of cancer.
The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018.
Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 9, 24 | 0.00 Increased by +100.00% | -0.11 Increased by +100.00% |
| Mar 12, 24 | -0.10 Decreased by -25.00% | -0.09 Decreased by -11.11% |
| Jan 16, 24 | -0.09 Increased by +25.00% | -0.09 |
| Sep 6, 23 | -0.08 Increased by +11.11% | -0.09 Increased by +11.11% |
| Jun 14, 23 | -0.07 Increased by +41.67% | -0.11 Increased by +36.36% |
| Mar 17, 23 | -0.08 Increased by +38.46% | -0.16 Increased by +50.00% |
| Jan 4, 23 | -0.12 Increased by +7.69% | -0.11 Decreased by -9.09% |
| Sep 9, 22 | -0.09 Increased by +35.71% | -0.13 Increased by +30.77% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jan 31, 24 | 0.00 Decreased by N/A% | -3.25 M Decreased by -53.54% | Decreased by N/A% Decreased by N/A% |
| Oct 31, 23 | 156.00 K Decreased by -99.99% | -2.69 M Increased by +20.79% | Decreased by -1.72 K% Decreased by -1.25 M% |
| Jul 31, 23 | 0.00 Decreased by N/A% | -2.51 M Increased by +7.07% | Decreased by N/A% Decreased by N/A% |
| Apr 30, 23 | 210.00 K Increased by +N/A% | -2.04 M Increased by +42.55% | Decreased by -969.05% Decreased by N/A% |
| Jan 31, 23 | 0.00 Decreased by N/A% | -2.12 M Increased by +44.63% | Decreased by N/A% Decreased by N/A% |
| Oct 31, 22 | 2.47 B Increased by +68.23 K% | -3.40 M Increased by +15.38% | Decreased by -0.14% Increased by +99.88% |
| Jul 31, 22 | 0.00 Decreased by N/A% | -2.70 M Increased by +37.66% | Decreased by N/A% Decreased by N/A% |
| Apr 30, 22 | 0.00 Decreased by N/A% | -3.54 M Decreased by -47.65% | Decreased by N/A% Decreased by N/A% |